Amino Acids & EnzymesApril 18, 20265 min read

Q-Bank Breakdown: Enzyme kinetics (Km, Vmax) — Why Every Answer Choice Matters

Clinical vignette on Enzyme kinetics (Km, Vmax). Explain correct answer, then systematically address each distractor. Tag: Biochemistry > Amino Acids & Enzymes.

Enzyme kinetics questions are the biochem version of “every word matters.” The vignette will look like it’s about a drug or a mutation, but what they’re really testing is whether you can translate a scenario into changes in KmK_m and VmaxV_{max}—and whether you can spot why each tempting distractor is wrong.

Tag: Biochemistry > Amino Acids & Enzymes


The Q-bank-style vignette

A 6-year-old boy is evaluated for recurrent kidney stones and photosensitivity. Labs show elevated urinary porphobilinogen and δ\delta-aminolevulinic acid. Genetic testing reveals decreased activity of an enzyme in heme synthesis due to a missense mutation. In vitro enzyme kinetics are performed comparing patient enzyme to wild type. The patient enzyme shows a lower maximal reaction rate but the substrate concentration required to reach half-maximal velocity is unchanged.

Which of the following best describes the kinetic changes?

A. Increased KmK_m, unchanged VmaxV_{max}
B. Decreased KmK_m, unchanged VmaxV_{max}
C. Unchanged KmK_m, decreased VmaxV_{max}
D. Unchanged KmK_m, increased VmaxV_{max}
E. Decreased KmK_m, decreased VmaxV_{max}


Step-by-step: translate the stem into kinetics

The stem basically hands you the definitions:

  • “Lower maximal reaction rate” \rightarrow decreased VmaxV_{max}
  • “Substrate concentration required to reach half-maximal velocity is unchanged” \rightarrow unchanged KmK_m (because KmK_m is the [S][S] at v=12Vmaxv = \frac{1}{2}V_{max})

So the correct choice is:

✅ Correct answer: C. Unchanged KmK_m, decreased VmaxV_{max}


Why this happens (the mechanism they’re aiming for)

A missense mutation that reduces enzyme activity often behaves like having less functional enzyme (or a lower catalytic rate), rather than altering substrate binding.

High-yield mapping:

  • VmaxV_{max} depends on enzyme amount and catalytic capacity:
    • Vmax=kcat[E]TV_{max} = k_{cat}[E]_T
    • If the enzyme is dysfunctional or effectively reduced in functional concentration, VmaxV_{max} falls.
  • KmK_m reflects affinity (roughly):
    • Lower KmK_m = higher apparent affinity
    • Higher KmK_m = lower apparent affinity
    • If binding is unchanged, KmK_m stays the same.

Clinically, “enzyme deficiency” questions commonly imply decreased VmaxV_{max} (less working enzyme), not necessarily a binding defect.


The visual: Lineweaver–Burk and Michaelis–Menten quick cues

Key landmarks

  • On a Lineweaver–Burk plot:
    • yy-intercept = 1Vmax\frac{1}{V_{max}}
    • xx-intercept = 1Km-\frac{1}{K_m}
    • slope = KmVmax\frac{K_m}{V_{max}}

What this vignette would show

  • Decreased VmaxV_{max} \rightarrow higher yy-intercept (1Vmax\frac{1}{V_{max}} increases)
  • Unchanged KmK_m \rightarrow same xx-intercept

Systematically destroying the distractors (why every answer choice matters)

A. Increased KmK_m, unchanged VmaxV_{max}

This pattern screams competitive inhibition (or decreased substrate affinity with intact catalytic machinery).

  • Competitive inhibitor:
    • increases KmK_m
    • does not change VmaxV_{max}
    • can be overcome by high substrate concentrations

Why it’s wrong here:

  • The stem explicitly says half-max substrate is unchanged \rightarrow KmK_m unchanged.
  • And it says max rate is lower \rightarrow VmaxV_{max} decreased.

USMLE hook: If the stem mentions a drug that resembles substrate (e.g., methotrexate vs folate; statins vs HMG-CoA), think competitive: Km\uparrow K_m, same VmaxV_{max}.


B. Decreased KmK_m, unchanged VmaxV_{max}

This would mean increased apparent affinity without changing maximal capacity—uncommon as a simple disease mutation vignette.

Where you might see decreased KmK_m:

  • An enzyme engineered or mutated to bind substrate more tightly (rarely tested clinically)
  • Certain allosteric activation concepts (though Step questions usually avoid forcing true Michaelis–Menten parameters onto allosteric enzymes)

Why it’s wrong here:

  • The stem states VmaxV_{max} is lower, not unchanged.

High-yield pearl: Don’t over-interpret “mutation” as “higher affinity.” Most pathogenic enzyme mutations reduce function (often lowering VmaxV_{max}).


C. Unchanged KmK_m, decreased VmaxV_{max}

Matches exactly.

Classic causes:

  • Noncompetitive inhibition (pure): inhibitor binds enzyme and ES equally well
  • Decreased enzyme concentration (or functional enzyme)
  • Catalytic defect: reduced kcatk_{cat} with preserved binding

Common USMLE phrasing that maps here:

  • “Decreased quantity of enzyme”
  • “Enzyme inactivated”
  • “Mutation decreases catalytic activity but not binding”

D. Unchanged KmK_m, increased VmaxV_{max}

This is basically “more effective enzyme capacity.”

What can raise VmaxV_{max}?

  • Increased enzyme concentration (induction)
  • Increased kcatk_{cat} (rare)
  • Removing an inhibitor (in an experimental setup)

Why it’s wrong here:

  • The stem explicitly says lower maximal rate, not higher.

Test strategy: When a question offers “increased VmaxV_{max},” look for language like “enzyme induction,” “upregulated expression,” or “increased enzyme concentration.” Absent that, it’s usually bait.


E. Decreased KmK_m, decreased VmaxV_{max}

This combination can be seen with uncompetitive inhibition (inhibitor binds only ES), which shifts both parameters down.

Uncompetitive inhibitor:

  • decreases VmaxV_{max}
  • decreases KmK_m
  • parallel Lineweaver–Burk lines (slope unchanged because KmVmax\frac{K_m}{V_{max}} stays constant)

Why it’s wrong here:

  • The stem says KmK_m unchanged, not decreased.

USMLE hook: Uncompetitive inhibition shows up when they emphasize binding to ES complex only, and it becomes more effective at higher substrate concentrations (because more ES exists).


High-yield kinetics cheat sheet (memorize this table)

SituationKmK_mVmaxV_{max}Lineweaver–Burk hallmark
Competitive inhibition\uparrowSame yy-int, xx-int moves toward 0
Noncompetitive (pure)\downarrowSame xx-int, yy-int increases
Uncompetitive inhibition\downarrow\downarrowParallel lines
Increased enzyme concentration\uparrowyy-int decreases
Decreased functional enzyme (loss-of-function)usually —\downarrowyy-int increases

Remember: In classic Michaelis–Menten questions, if binding changes, KmK_m changes. If capacity changes, VmaxV_{max} changes.


Mini-clinical tie-in: why the stem mentions heme synthesis at all

The porphyria flavor text is there to make it feel clinical, but the kinetics question stands on its own. Still, Step exams love bridging:

  • Many inborn errors reduce effective enzyme activity (less functional enzyme)
  • That commonly presents kinetically as decreased VmaxV_{max}
  • Unless the stem explicitly hints at altered binding/affinity, assume KmK_m is unchanged

Exam-day approach (fast and reliable)

  1. Circle “half-max velocity substrate concentration” \rightarrow KmK_m clue
  2. Circle “max rate” or “plateau” \rightarrow VmaxV_{max} clue
  3. Ask: is this a binding problem (affinity) or a capacity problem (amount/function)?
  4. Match to inhibitor patterns only if the stem describes an inhibitor-like scenario.